CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04824794
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:46.431888+00:00
Published At: 2025-12-22T00:00:00+00:00
Record Updated At: 2025-12-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Relapsed or Refractory Multiple Myeloma (RRMM)", "Diffuse Large B Cell Lymphoma (DLBCL)", "Acute Myeloid Leukemia (AML)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-22"
protocolSection.identificationModule.nctId: "NCT04824794"
protocolSection.identificationModule.officialTitle: "An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody\u00ae-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.